These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29975242)

  • 1. Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease.
    Bohn Thomsen S; Kiszka-Kanowitz M; Theede K; Gluud LL; Mertz Nielsen A
    Eur J Gastroenterol Hepatol; 2018 Oct; 30(10):1155-1158. PubMed ID: 29975242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.
    Brooks AJ; Sebastian S; Cross SS; Robinson K; Warren L; Wright A; Marsh AM; Tsai H; Majeed F; McAlindon ME; Preston C; Hamlin PJ; Lobo AJ
    J Crohns Colitis; 2017 Dec; 11(12):1456-1462. PubMed ID: 25311864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.
    Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Romanko I; Bina V; Malickova K; Kolar M; Lukas M
    Scand J Gastroenterol; 2016; 51(2):196-202. PubMed ID: 26329773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Crohn's disease relapse with faecal calprotectin in infliximab responders: a prospective study.
    Laharie D; Mesli S; El Hajbi F; Chabrun E; Chanteloup E; Capdepont M; Razaire S; de Lédinghen V; Zerbib F
    Aliment Pharmacol Ther; 2011 Aug; 34(4):462-9. PubMed ID: 21671970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Ferreiro-Iglesias R; Barreiro-de Acosta M; Lorenzo-Gonzalez A; Dominguez-Muñoz JE
    Scand J Gastroenterol; 2016; 51(4):442-7. PubMed ID: 26595391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early change in faecal calprotectin predicts primary non-response to anti-TNFα therapy in Crohn's disease.
    Pavlidis P; Gulati S; Dubois P; Chung-Faye G; Sherwood R; Bjarnason I; Hayee B
    Scand J Gastroenterol; 2016 Dec; 51(12):1447-1452. PubMed ID: 27400728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapse rates of inflammatory bowel disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy.
    Hlavaty T; Krajcovicova A; Letkovsky J; Sturdik I; Koller T; Toth J; Huorka M
    Bratisl Lek Listy; 2016; 117(4):205-11. PubMed ID: 27075383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas.
    Tozer P; Ng SC; Siddiqui MR; Plamondon S; Burling D; Gupta A; Swatton A; Tripoli S; Vaizey CJ; Kamm MA; Phillips R; Hart A
    Inflamm Bowel Dis; 2012 Oct; 18(10):1825-34. PubMed ID: 22223472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum calprotectin as a biomarker for Crohn's disease.
    Meuwis MA; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Piver E; Seidel L; Colombel JF; Louis E;
    J Crohns Colitis; 2013 Dec; 7(12):e678-83. PubMed ID: 23845231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-α antibodies.
    Eder P; Stawczyk-Eder K; Korybalska K; Czepulis N; Luczak J; Lykowska-Szuber L; Krela-Kazmierczak I; Linke K; Witowski J
    World J Gastroenterol; 2017 Jan; 23(1):135-140. PubMed ID: 28104989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease.
    Mak JWY; Tang W; Yip TCF; Ran ZH; Wei SC; Ahuja V; Kumar S; Leung WK; Hilmi I; Limsrivilai J; Aniwan S; Lam BCY; Chan KH; Ng KM; Leung CM; Li MKK; Lo FH; Sze ASF; Tsang SWC; Hui AJ; Hartono JL; Ng SC
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1195-1203. PubMed ID: 31638274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.
    Molander P; Sipponen T; Kemppainen H; Jussila A; Blomster T; Koskela R; Nissinen M; Rautiainen H; Kuisma J; Kolho KL; Färkkilä M
    J Crohns Colitis; 2013 Oct; 7(9):730-5. PubMed ID: 23182163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Bots SJ; Kuin S; Ponsioen CY; Gecse KB; Duijvestein M; D'Haens GR; Löwenberg M
    Scand J Gastroenterol; 2019 Mar; 54(3):281-288. PubMed ID: 30907185
    [No Abstract]   [Full Text] [Related]  

  • 15. Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.
    Molander P; af Björkesten CG; Mustonen H; Haapamäki J; Vauhkonen M; Kolho KL; Färkkilä M; Sipponen T
    Inflamm Bowel Dis; 2012 Nov; 18(11):2011-7. PubMed ID: 22223566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year.
    Guidi L; Marzo M; Andrisani G; Felice C; Pugliese D; Mocci G; Nardone O; De Vitis I; Papa A; Rapaccini G; Forni F; Armuzzi A
    Dig Liver Dis; 2014 Nov; 46(11):974-9. PubMed ID: 25096964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accuracies of serum and fecal S100 proteins (calprotectin and calgranulin C) to predict the response to TNF antagonists in patients with Crohn's disease.
    Boschetti G; Garnero P; Moussata D; Cuerq C; Préaudat C; Duclaux-Loras R; Mialon A; Drai J; Flourié B; Nancey S
    Inflamm Bowel Dis; 2015 Feb; 21(2):331-6. PubMed ID: 25625487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined evaluation of biomarkers as predictor of maintained remission in Crohn's disease.
    Sollelis E; Quinard RM; Bouguen G; Goutte M; Goutorbe F; Bouvier D; Pereira B; Bommelaer G; Buisson A
    World J Gastroenterol; 2019 May; 25(19):2354-2364. PubMed ID: 31148906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.
    Pittet V; Froehlich F; Maillard MH; Mottet C; Gonvers JJ; Felley C; Vader JP; Burnand B; Michetti P; Schoepfer A;
    J Crohns Colitis; 2013 Nov; 7(10):820-6. PubMed ID: 23664620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission?
    Molander P; Färkkilä M; Ristimäki A; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    J Crohns Colitis; 2015 Jan; 9(1):33-40. PubMed ID: 25052347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.